Last update July 16, 2017

Eslicarbazepine

Likely Compatibility

Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.

Eslicarbazepine or S-licarbazepine is the S-enantiomer of licarbazepine (MHD), the active metabolite of oxcarbazepine (see specific information), an anti-epileptic drug considered to be of low risk during breastfeeding.

Since the last update we have not found any published data on its excretion in breast milk.

Given the structural equivalence and similar actions to oxcarbazepine, different effects are not likely in infants who are breastfed by mothers undergoing treatment with eslicarbazepine or oxcarbazepine, but until there is more data on this drug in relation to breastfeeding, safer known alternatives are preferred, especially in the neonatal period and in case of prematurity.


See below the information of this related product:

  • Oxcarbazepine (Safe product and/or breastfeeding is the best option.)

Alternatives

  • Carbamazepine (Safe product and/or breastfeeding is the best option.)
  • Oxcarbazepine (Safe product and/or breastfeeding is the best option.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Eslicarbazepine is also known as


Eslicarbazepine in other languages or writings:

Group

Eslicarbazepine belongs to this group or family:

Tradenames

Main tradenames from several countries containing Eslicarbazepine in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 90 %
Molecular weight 254 daltons
Protein Binding 40 %
VD 0.9 l/Kg
Tmax 2 - 3 hours
T½ 20 - 24 hours

References

  1. Cabo-Lopez I, Canneti B, Puy-Nunez A. Epilepsia y lactancia materna: del mito a la realidad. [Epilepsy and breastfeeding: from myth to reality]. Rev Neurol. 2019 Jul 16;69(2):68-76. Abstract
  2. EMA. Eslicarbazepina. Ficha técnica. 2016 Full text (in our servers)
  3. EMA. Eslicarbazepine. Drug Summary. 2016 Full text (in our servers)
  4. Jacob S, Nair AB. An Updated Overview on Therapeutic Drug Monitoring of Recent Antiepileptic Drugs. Drugs R D. 2016 Abstract Full text (link to original source) Full text (in our servers)
  5. Sunovion. Eslicarbazepine (Aptiom). Prescribing Information. 2015 Full text (in our servers)

Total visits

4,281

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM